Introduction
============

Despite recent developments in postoperative pain management, many patients still suffer from moderate-to-severe pain after surgery. It is estimated that postoperative severe pain occurs in 20%--40% of all surgical procedures.[@b1-jpr-11-2123] Pain during the first days after surgery might lead to severe complications, such as delayed ambulation, increased incidence of cardiovascular and pulmonary complications with increased morbidity and mortality, and the development of chronic postoperative pain.[@b1-jpr-11-2123]--[@b6-jpr-11-2123] Therefore, the proper treatment of postoperative pain is of great importance, especially in procedures that lead to severe pain.

The prevalence of morbid obesity is increasing in most countries, and there is a growing demand for surgical procedures in these patients (both related and not related to obesity). The postoperative pain management in these patients is especially important, considering this population has greater susceptibility to cardiovascular, pulmonary, and thromboembolic complications in the perioperative period.[@b7-jpr-11-2123]--[@b9-jpr-11-2123]

Methadone is a strong µ-opioid receptor (MOR) agonist. It antagonizes glutamate by blocking the *N*-methyl-[d]{.smallcaps}-aspartate receptor (NMDAr) and inhibits the reuptake of serotonin and noradrenaline in the central nervous system. When used parenteral, its latency is of 10--20 minutes, with 4--36 hours of action, depending on the dosage, due to its long half-life and the large individual variation.[@b10-jpr-11-2123],[@b11-jpr-11-2123] When administered in doses of 20--30 mg, analgesia generated by intravenous (i.v.) methadone can last from 24 to 36 hours.[@b12-jpr-11-2123]

Methadone may be an interesting option in the treatment of postoperative pain, and the dose used in anesthesia may contribute to immediate postoperative analgesia, when the highest pain scores are usually reported. Few published studies have compared intraoperative methadone to fentanyl or sufentanil in cardiac surgery,[@b13-jpr-11-2123],[@b14-jpr-11-2123] spine surgery,[@b15-jpr-11-2123] laparoscopy,[@b16-jpr-11-2123] hysterectomy,[@b17-jpr-11-2123],[@b18-jpr-11-2123] abdominal surgery,[@b18-jpr-11-2123],[@b19-jpr-11-2123] and major surgery in children.[@b20-jpr-11-2123] To our knowledge, no study has compared the use of intraoperative methadone with other opioids for the morbidly obese patients.

The present study was designed to evaluate the efficacy and safety of intraoperative i.v. methadone in reducing postoperative pain and opioid consumption in morbidly obese patients submitted to open bariatric surgery.

Materials and methods
=====================

This study was approved by the University of São Paulo Institutional Review Board (identifier 1.412.317) and written informed consent was obtained from all subjects participating in the trial. The trial was registered prior to patient enrollment at [ClinicalTrials.gov](http://ClinicalTrials.gov) (NCT02775474, principal investigator: FCM, date of registration: May 17, 2016).

Subjects included were submitted to open bariatric surgery (with or without Rouxen-Y anastomosis) performed by the same team of surgeons and anesthetists. The inclusion criteria were American Society of Anesthesiologists II patients, aged 18--65 years scheduled for bariatric surgery. The exclusion criteria were refusal by the patient, cardiac or coronary disease, cardiac conduction abnormalities (QT interval duration of 450 ms or more), creatinine clearance lower than 60 mL/min, psychiatric mood or personality disorders, use of preoperative opioids or history of opioid misuse, and allergy to any of the study used drugs. Patients were allocated into two groups using computer-generated randomization, and demographic data were obtained. This manuscript adhered to the applicable Consolidated Standards of Reporting Trials guidelines.

A nonblind medical assistant prepared the induction syringe and the opioid bolus solution for each patient. This assistant did not participate in any other part of data collection and patient information and allocation were kept in opaque sealed envelopes. All other assistants and health professionals involved were blinded, including preoperative, intraoperative and postoperative assessments. The induction syringe contained either methadone 0.15 mg/kg (group M) or fentanyl 6 µg/kg (group F), and each 5 mL bolus of the opioid bolus solution contained either methadone 0.05 mg/kg or fentany l 2 µg/kg. These doses have been demonstrated to be approximately equipotent[@b21-jpr-11-2123]--[@b23-jpr-11-2123] and were diluted in a standardized format so that the final presentation was identical for both groups. The weight used to calculate the dosages was the ideal body weight (IBW) plus 20% calculated by Robinson's formula,[@b24-jpr-11-2123] which is the most precise equation currently available to determine IBW.[@b25-jpr-11-2123]

Anesthesia was induced with i.v. midazolam (3 mg), propofol titrated until loss of consciousness, and cisatracurium (0.15 mg/kg total body weight). At induction, the patients received either methadone (0.15 mg/kg IBW+20%) or fentanyl (6 µg/kg IBW+20%). Maintenance of anesthesia consisted of sevoflurane 1.8%--2.2% and repeated boluses of cisatracurium for optimal surgical relaxation. Hypotension (decrease of 20% or more in initial blood pressure) was treated with boluses of metaraminol (0.5 mg) or ephedrine (5 mg) as clinically indicated. Hypertension (any value higher than initial blood pressure) was treated with boluses from the same induction opioid: either methadone (0.05 mg/ kg IBW+20%) or fentanyl (2 µg/kg IBW+20%) every 10 minutes if necessary. The opioid dilution was calculated so the anesthesiologist would always administer 5 mL of the opioid bolus solution if needed. Monitoring consisted of a five-lead electrocardiogram, pulse oximetry, noninvasive pressure monitoring, esophageal temperature, capnography, and gas analyzer. Adjuvants were used for an optimal multimodal analgesia and prevention of postoperative nausea and vomiting (PONV) at the beginning of the procedure (pantoprazole 40 mg, dexamethasone 4 mg, and ketoprofen 100 mg) and at its end (dipyrone 2 g, ondansetron 4 mg, and morphine 3 mg). A median upper abdominal incision was performed in all subjects, and all incisions were infiltrated with 20 mL of 0.375% ropivacaine by the surgeon. Prior to extubation, all patients received neostigmine 30 µg/kg and atropine 15 µg/kg. After extubation, if hypoventilation (respiratory rate less than 8) refractory to continuous positive airway pressure for 15 minutes occurred, naloxone 40 µg was administered.

All patients used patient-controlled analgesia (PCA) (Hospira, Gemstar 7 Therapy^®^) for postoperative analgesia, installed in the operating room before transport to postanesthesia care unit (PACU). All PCA devices contained a 0.1% i.v. morphine solution, with a bolus of 2 mg, lockout interval of 5 minutes, and a 4 hour bolus limit of 30 mg. In addition, all patients received i.v. dipyrone 2 g every 6 hours.

In PACU, patients were monitored with electrocardiogram, pulse oximetry, and noninvasive pressure monitoring; patients remained in PACU for 2 hours before discharged to the ward.

Patients were assessed for pain using the visual analog pain score (VAS based on a 0--10 scale; 0 = no pain and 10 = worst pain possible) and side effects 10 minutes after extubation. The Richmond Agitation -Sedation Scale (RASS) was used to evaluate sedation, and the anesthesia awakening time was recorded. If the patient was complaining of pain, he or she was reminded that the PCA device was available for use. The PCA device was available for 48 hours after surgery. After 48 hours, boluses of morphine were prescribed as needed.

The primary outcome was postoperative morphine consumption at 2, 6, 24, 48, and 72 hours after surgery. Secondary outcomes were pain score (VAS) at rest and while coughing, opioid-related side effects (nausea, vomiting, pruritus, urinary retention, and the necessity for supplementary oxygen), and sedation score (RASS) at 10 minutes after extubation and at 2, 6, 24, 48, and 72 hours postoperatively. Patient satisfaction with postoperative pain management was accessed at 24, 48, and 72 hours after surgery using a scale of 0= unsatisfied to 10= completely satisfied. Patients were also evaluated 3 months after surgery for the presence of spontaneous or evoked pain and the presence of dysesthesia or paresthesia in the incision area. Evoked pain was evaluated by manual palpation in and around the scar by the researcher. All care providers and research team members responsible for data collection were blinded to group assignment throughout the perioperative period.

We used the primary outcome measure to estimate the sample size. The average morphine consumption for this procedure observed from 20 previous patient's data was 28 mg in the first 24 hours after surgery. Following other study results, we estimated that a 40% reduction in morphine consumption would be considered as clinically meaningful. Fifty-six patients were needed to detect the 40% difference in the postoperative morphine consumption between the groups, with a SD of 6%, a test power of 80%, and level of significance of 5%.

Statistical analysis
--------------------

Means were compared using the Student's *t*-test for normally distributed data, and medians were compared with Kruskal--Wallis test if the data were not normally distributed. Fisher's exact test was used to compare proportions. Two-way repeated-measures ANOVA was conducted with post hoc Bonferroni correction. Statistical tests were two-sided and performed at a significance level of 0.05.

Results
=======

A total of 56 patients were scheduled to be included in the study. However, during the study, two clear different patterns of morphine consumption among patients were observed, with some patients consuming very low dosages of morphine while others consuming large amounts of morphine, and a preliminary analysis was performed by a nonblinded researcher. This analysis showed statistically relevant results and the recruitment stopped since one method of anesthesia was superior to the other, and patients that received fentanyl, group F, were using avoidable high doses of morphine. As a result, the analysis considered a total of 32 patients enrolled in the study, 16 in each group ([Figure 1](#f1-jpr-11-2123){ref-type="fig"}). Both groups were similar regarding demographic and clinical characteristics ([Table 1](#t1-jpr-11-2123){ref-type="table"}). During anesthesia, both groups had similar intraoperative requirements regarding the opioid boluses needed, propofol dose at induction, the number of vasopressor boluses needed, intraoperative hydration, duration of anesthesia, and awakening time.

As for the primary outcome, group F postoperative mean morphine consumption was 6.5 mg (95% CI 3.2--9.7) at 2 hours, 12.5 mg (95% CI 7.4--17.1) at 2--6 hours, 13.5 mg (95% CI 8.3--18.7) at 6--24 hours, 16.6 mg (95% CI 6.1--27.2) at 24--48 hours, and 4.2 (95% CI −0.3 to 8.6) at 48--72 hours. Group M postoperative mean morphine consumption was 0.1 mg (95% CI −0.1 to 0.4) at 2 hours, 0.9 mg (95% CI 0.2--1.6) at 2--6 hours, 3.1 mg (95% CI 1.9--4.4) at 6--24 hours, 2.1 mg (95% CI 0.8--3.4) at 24--48 hours, and 0.2 (95% CI −0.1 to 0.6) at 48--72 hours.

When comparing both groups, the postoperative morphine consumption was significantly higher in group F than group M until 48 hours and at the moments or intervals of 2 hours (mean difference \[MD\] 6.4 mg; 95% CI 3.1--9.6; *P*\<0.001), 2--6 hours (MD 11.4 mg; 95% CI 6.5--16.2; *P*\<0.001), 6--24 hours (MD 10.4 mg; 95% CI 5.0--15.7; *P*\<0.001), and 24--48 hours (MD 14.5 mg; 95% CI 3.9--25.1; *P*=0.01). There was no difference in the opioid requirement in the 72-hour evaluation (MD 3.9 mg; 95% CI −0.5 to 8.4; *P*=0.08) ([Figure 2](#f2-jpr-11-2123){ref-type="fig"}).

Pain scores at rest were higher in group F at 2 hours (MD 3.1; 95% CI 1.9--3.2; *P*\<0.001), 6 hours (MD 2.4; 95% CI 1.5--3.3; *P*\<0.001), and 24 hours (MD 0.9; 95% CI 0.2--1.5; *P*=0.001) than group M. There was no statistical difference between the groups in the 48 hours (MD 0.2; 95% CI −0.1 to 0.6; *P*=0.13) and 72 hours (MD 0.1; 95% CI −0.1 to 0.4; *P*=0.3) postoperative scores. Pain scores at coughing were higher in group F at 2 hours (MD 5.3; 95% CI 4.1--6.5; *P*\<0.001), 6 hours (MD 3.4; 95% CI 2.4--4.5; *P*\<0.001), 24 hours (MD 2.6; 95% CI 1.3--3.9; *P*\<0.001), and 72 hours (MD 1.2; 95% CI 0.3--2.2; *P*=0.02), and no difference was observed at 48 hours between the two groups (MD 1.1; 95% CI −0.1 to 2.2; *P*=0.05) ([Figure 3](#f3-jpr-11-2123){ref-type="fig"}).

Ten minutes after extubation, RASS score was similar in both groups, but group F patients had higher pain scores (VAS: mean 1.37; range 0--7) than group M patients (VAS: 0 for all patients at this evaluation; *P*\<0.01; Kruskal--Wallis test). PONV was more common in group F than in group M at 10-minutes evaluation (37.5% vs 0%; *P*=0.02; Fisher's exact test). The perioperative results are shown in [Table 2](#t2-jpr-11-2123){ref-type="table"}. Opioid antagonist use was necessary in one patient of each group.

Opioid-related side effects occurred more frequently in group F than in group M for nausea (75% vs 6.3%; *P*=0.001; Fisher's exact test) and vomiting (31.3% vs 0%; *P*=0.001; Fisher's exact test). The incidence of pruritus, need for supplementary oxygen, and RASS sedation scores were similar between the groups ([Table 3](#t3-jpr-11-2123){ref-type="table"}). No patient had urinary retention; all patients scored 0 at RASS score at 24-, 48-, and 72-hour postoperative evaluations. No patients presented score higher than zero or lower than --2 at any of the postoperative evaluations. Also, no patient required supplementary oxygen for more than 6 hours postoperatively.

The median patient satisfaction score was also lower for group F compared with group M at 24 hours (8.5, range 6--10 vs 10, range 9--10; *P*=0.004; Kruskal--Wallis test), 48 hours (9.0, range 6--10 vs 10, range 9--10; *P*=0.015; Kruskal--Wallis test), and 72 hours (9.5, range 7--10 vs 10, range 9--10; *P*=0.015; Kruskal--Wallis test) postoperatively.

At the 3-month postoperative evaluation, both groups had similar pain at rest (*P*=0.6; Fisher's exact test), pain while coughing (*P*=0.39; Fisher's exact test), and dysesthesia symptoms (*P*=1.0; Fisher's exact test). However, group F had more evoked pain at surgical scar palpation (56% vs 12.5%; *P*=0.02; Fisher's exact test) than group M.

Discussion
==========

Methadone in bariatric surgery showed to be safe and significantly reduced the postoperative opioid consumption, pain scores at rest and at movement, less opioid-related nausea and vomiting, and better patient satisfaction. Intraoperative methadone usage is relatively new in anesthesia and has not yet been extensively studied. This is the first trial to analyze intraoperative methadone use and postoperative pain management of morbidly obese patients.

Our primary outcome was postoperative morphine consumption. Patients receiving fentanyl had a higher need for opioid usage in the postoperative period until 48 hours. This result was greater than the initially proposed 40% difference in morphine consumption. These findings are consistent with other trials studying methadone as the sole opioid in anesthesia for nonobese patients.[@b13-jpr-11-2123],[@b15-jpr-11-2123],[@b17-jpr-11-2123] Secondary outcomes as pain at rest and while coughing were higher in group F right after extubation and 24 hours after surgery. Lower postoperative pain scores for methadone use are also in accordance with other studies conducted in nonobese patients.[@b13-jpr-11-2123],[@b15-jpr-11-2123],[@b17-jpr-11-2123]

Patients receiving fentanyl experienced more opioid-related side effects right after extubation and in the postoperative period until 72 hours. Patients on methadone presented less PONV. The incidences of pruritus, sedation, need for supplementary oxygen, and urinary retention were similar between groups. Patients were monitored with ECG for 2 hours at PACU, and no QT interval alterations were observed in both groups. Side effects with different opioids is still controversial in literature with some studies showing no difference in opioid-related side effects when comparing methadone with other opioids[@b13-jpr-11-2123],[@b15-jpr-11-2123],[@b17-jpr-11-2123],[@b18-jpr-11-2123] and one study that reported less of such side effects in the group that used methadone.[@b14-jpr-11-2123]

Satisfaction with the postoperative pain management was higher among patients under methadone compared with those receiving fentanyl. We believe this is a consequence of the better analgesia provided by methadone, although the use of PCA is usually related to high scores of patient satisfaction since it easily alleviates pain when used. One study compared patient satisfaction with methadone versus fentanyl for cardiac surgery and found similar results.[@b13-jpr-11-2123]

All patients in this study were submitted to the same protocol of general anesthesia and the same bariatric surgery technique. Intraoperative variables such as opioid, propofol and vasopressor boluses requirement, intraoperative hydration, duration of anesthesia, and awakening time were similar in both groups.

The methadone favorable outcomes in postoperative opioid consumption and pain scores could be the result of a combination of factors. Methadone has a longer elimination half-life (13--50 hours)[@b10-jpr-11-2123],[@b12-jpr-11-2123],[@b19-jpr-11-2123] than fentanyl (8--10 hours),[@b26-jpr-11-2123] which may lead methadone to maintain an analgesic effect longer than fentanyl. In addition, fentanyl has an analgesic mechanism of action by acting as an MOR agonist; meanwhile methadone is MOR agonist but also antagonizes glutamate by blocking the NMDAr and inhibits reuptake of serotonin and noradrenaline.[@b12-jpr-11-2123] These other effects in pain transmission can enhance the analgesic potential of methadone when used in anesthesia compared with fentanyl. Probably the higher postoperative morphine consumption in the group has led to the higher incidence of PONV observed.

This is the first study to establish an evaluation for postoperative chronic pain in this population (pain for a period of longer than 2 months)[@b27-jpr-11-2123] and pain 3 months after surgery. No statistical differences at the spontaneous pain and dysesthesia symptoms occurred between the two groups, but patients of group M presented lower evoked pain scores after the mechanical stimulus. There is consistent evidence that a better postoperative analgesia is related to less chronic pain after surgery.[@b28-jpr-11-2123] The most important limitation for these results is that the sample size was not calculated for chronic postoperative pain. So, more data on chronic pain after surgery with different interventions are necessary to understand the long-term impact of different multimodal analgesia methods. Despite the evidence that better postoperative analgesia is related to less chronic pain after surgery, no other methadone-related trial has yet conducted a long-term patient evaluation.

Many practitioners would choose to avoid methadone for the target population of this study favoring short-acting opioids or no opioids because of the long and variable half-life of methadone in a population prone to sleep apnea and airway obstruction. The results suggested otherwise, that the use of methadone as sole opioid in bariatric surgery for morbidly obese patients was safe and significantly reduced the postoperative opioid consumption, leading to lower pain scores at rest and at movement, less opioid-related nausea and vomiting, and better patient satisfaction.
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![Postoperative morphine consumption (mg).\
**Note:** Data are mean (horizontal black straight segment), SD (boxplot: blue or green), and min and max (vertical black straight segment).](jpr-11-2123Fig2){#f2-jpr-11-2123}

![Postoperative pain scores.\
**Notes: (A)** Pain scores while coughing. **(B)** Pain scores at rest. Data are mean (horizontal black straight segment), SD (boxplot: blue or green), and min and max (vertical black straight segment). When no patient reported pain (VAS= 0), only a small horizontal line is presented.\
**Abbreviation:** VAS, visual analog pain score.](jpr-11-2123Fig3){#f3-jpr-11-2123}

###### 

Patient characteristics

  Characteristic                                                            Group F      Group M
  ------------------------------------------------------------------------- ------------ ------------
  N                                                                         16           16
  Sex (female)                                                              13 (81.2%)   11 (68.7%)
  Age (years)                                                               43.2±11.0    46.2±13.3
  Body mass index (kg/m^2^)                                                 44.2±9.4     47.6±5.7
  ASA physical status                                                       2 (100%)     2 (100%)
  Smoking history                                                           5 (31.2%)    7 (43.7)%
  Drinking history                                                          0            0
  Hypertension                                                              10 (62.5%)   12 (75%)
  Resistant hypertension[a](#tfn2-jpr-11-2123){ref-type="table-fn"}         5 (31.2%)    5 (31.2%)
  IDDM                                                                      2 (12.5%)    1 (6.2%)
  NIDDM                                                                     6 (37.5%)    6 (37.5%)
  Thyroid disease                                                           4 (25%)      2 (12.5%)
  Dyslipidemia                                                              5 (31.2%)    6 (37.5%)
  Sleep apnea                                                               2 (12.5%)    3 (18.7%)
  Chronic musculoskeletal pain[b](#tfn3-jpr-11-2123){ref-type="table-fn"}   6 (37.5%)    5 (31.2%)
  APFEL score                                                               2.5 (2--3)   2.3 (2--3)

**Notes:** Data are mean ± SD (normal distribution), median \[min -- max\] (non-normal distribution), or number of patients (%).

Hypertension that remains uncontrolled (140/90 mmHg or higher) despite an optimal two-drug regimen that has had adequate time to work (at least 1 month since last drug or dosage adjustment).

Pain for more than 3 months. Reported sites of pain were knees (18% of n=32), lumbar (15% of n=32), and hip (9% of n=32). Drinking history= alcohol consumption of more than two drinks per day.

**Abbreviations:** ASA, American Society of Anesthesiologists; IDDM, insulin-dependent diabetes mellitus; NIDDM, non-insulin-dependent diabetes mellitus.

###### 

Perioperative period: intraoperative and 10 minutes after extubation

  Perioperative evaluations                                                         Group F (n=16)       Group M (n=16)       *P*-value
  --------------------------------------------------------------------------------- -------------------- -------------------- -----------
  Propofol requirement at induction (mg)                                            130±39.8             141.9±54.7           0.49
  Volume of opioid boluses needed (mL)[a](#tfn6-jpr-11-2123){ref-type="table-fn"}   25.3±7.2             21.6±6.8             0.14
  Vasopressor bolus requirement (n)[b](#tfn7-jpr-11-2123){ref-type="table-fn"}      2 \[0--12\]          0.5 \[0--10\]        0.16
  Intraoperative crystalloids (mL)                                                  1900±468.7           1887±332.4           0.93
  Length of anesthesia (minutes)                                                    250.0 \[220--310\]   250.0 \[220--300\]   0.73
  Awakening time (minutes)                                                          16.4±3.0             16.8±4.1             0.77
  RASS 10 minutes after extubation (−5 to +4)                                       −1.0 \[−4 to 0\]     −1.1 \[−3 to 0\]     0.23
  Pain score 10 minutes after extubation (0--10)                                    0 \[0--7\]           0 \[0--0\]           \<0.01
  Nausea 10 minutes after extubation (n)                                            6 (37.5%)            0                    0.02

**Notes:** Variables with normal distribution are shown in each group as "mean ± SD" and "*P*-value" calculated with Student's *t*-test. Variables with non-normal distribution are shown as "median \[min--max\]" and "*P*-value" calculated with Kruskal--Wallis test. Proportions are shown in each group as "n (%)" and "*P*-value" calculated with Fisher's exact test.

Milliliters of a standardized opioid solution used for identical final aspect in both groups.

Standardized bolus of metaraminol or ephedrine.

**Abbreviation:** RASS, Richmond Agitation -Sedation Scale.

###### 

Postoperative opioid-related side effects -- n (%)

  -----------------------------------------------------------------------------------------------------------------------------------------
  Side effects                                            Group F\     Group M\      *P*-value[a](#tfn9-jpr-11-2123){ref-type="table-fn"}
                                                          (n=16)       (n=16)        
  ------------------------------------------------------- ------------ ------------- ------------------------------------------------------
  Nausea                                                  12 (75%)     1 (6.25%)     0.001

  Vomiting                                                5 (31.25)    0             0.001

  Pruritus                                                4 (25%)      0             0.10

  Need for supplementary oxygen 2 hours postoperatively   14 (87.5%)   11 (68.75%)   0.39

  Need for supplementary oxygen 6 hours postoperatively   4 (25%)      2 (12.5%)     0.65

  RASS lower than 0 at 2 hours                            10 (62.5%)   5 (31.25)     0.16

  RASS lower than 0 at 6 hours                            2 (12.5%)    2 (12.5%)     1
  -----------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Fisher's exact test.

**Abbreviation:** RASS, Richmond Sedation and Agitation Scale.
